CEL-SCI Corporation (AMEX:CVM) jumped 17.17% to close at $0.63 with 1,919,446 shares moving on no official news; however Tuesday at this year’s annual BIO CEO & Investor Conference,  the company’s CEO presented the benefits of its lead cancer therapeutic, Multikine, which was later brutally rebuffed in an online article published by an investment researcher for TheStreet.com, which sent the stock tumbling about 10% that day. Based in Vienna, Virginia, CEL-SCI Corporation researches and develops drugs and vaccines used in the treatment of cancer and viral infections, the company has been actively researching possible variations and eventual mutations of the swine flu.

NexMed, Inc. (NASDAQ:NEXM) up 8.70% to close at $0.039 on no news since the company announced a private placement of $2.3 million; and the sale of its New Jersey state tax credits and net operating losses which raised $438,000 in net proceeds. In January the company announced that pre-clinical results confirmed the ability of the company’s NexACT technology to orally administer chemotherapy drug Taxol, and sent the stock surging 85%. Headquartered in East Windsor, New Jersey, NexMed, Inc. develops bio-enhancement drug delivery technology known as NexACT, which enables an active drug to be better absorbed through the skin.  NexMed has 3 drug candidates at mid stage trial and expects a decision from Health Canada in February 2010 concerning approval of Vitaros, a topical treatment for erectile dysfunction.  NEXM’s 52 week high sits at $0.74; the stock is trading above its 200 day moving average of $0.27, and overall has appreciated 71% in 2010.

Opexa Therapeutics Inc. (NASDAQ:OPXA) advanced 8.81% to close at $2.10, on no news. Based in The Woodlands, Texas, Opexa Therapeutics, Inc. develops patient-specific cellular therapies for the treatment of autoimmune diseases including multiple sclerosis (MS) and diabetes. The proprietary therapies are based on adult stem cell technologies and include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) gained 13.18% to close at $0.91 on no news with 2,251,436 shares traded. Recently the company granted Carmot Therapeutics, Inc., an exclusive license to its proprietary Fragment-Based Lead Discovery (FBLD) technology. Carmot will use the FBLD technology, called “Chemotype Evolution,” for identifying promising drug candidates in a broad range of therapeutic areas, including inflammatory, metabolic, and neurodegenerative diseases. Sunesis retains full rights to the technology for use in its future internal discovery efforts; however terms of the agreement were not revealed.  The company disclosed promising developments at the end of 2009: a Phase 2 Voreloxin study for leukemia proved that patients who dosed Voreloxin combined with chemotherapy had an increased survival rate. Patients with acute myeloid leukemia usually live for only about three to six months. Headquartered in South San Francisco, California, Sunesis Pharmaceuticals, Inc is a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumour cancers. Its primary product candidate is Voreloxin; an anticancer treatment is in Phase 2 development stage.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) up 18.27% to close at $2.33 after hitting an intra-day high of $2.43, on no news. The company’s lead drug candidate Seliciclib was examined by two medical journals in January and found to be successful in killing lung cancer cells through induction of cancer cell suicide; the stock jumped 152% to a 52 week high of $2.96. Headquartered in Berkeley Heights, New Jersey, Cyclacel Pharmaceuticals, Inc., is a development-stage biopharmaceutical company which discovers, develops, and commercializes novel, mechanism-targeted drugs to treat human cancers and other serious illnesses.  The company currently has 3 drug candidates in 7 clinical trial studies for the treatment of various cancers.  CYCC is trading above its 200 day moving average of $1.21 and has gained 717% from a low of $0.028 last February.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Opko Health Inc. (AMEX:OPK) jumped 21.83% up $2.12 on news the company has developed a simple blood test for Alzheimer’s disease, which assess the levels of antibodies unique to the disease with 95% accuracy. Headquartered in Miami, Florida, Opko Health, Inc., is a specialty healthcare company discovering, developing, and commercializing its proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of various disorders.

Rexahn Pharmaceuticals, Inc. (AMEX:RNN) rose 16.29% up to $0.919 on no news.  The stock’s intra-day high is sitting at $0.95 and trading above its 200 day moving average of $0.810. Based in Rockville, Maryland, Rexahn Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company which discovers, develops, and commercializes treatments for cancer, central nervous system disorders, sexual dysfunction in the US. The company currently has three drug candidates in Phase II clinical trials which include Serdaxin for the treatment of depression, Archexin for the treatment of renal cell carcinoma and pancreatic cancer; and Zoraxel for the treatment of sexual dysfunction.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Athersys, Inc. (NASDAQ:ATHX) jumped 27.78% up to $3.68 on heavy volume with 5,479,849 shares trading on news the company was issued two US patents protecting the intellectual rights to its non-embryonic multipotent stem cells, the applications of isolation and expansion, and related pharmaceutical compositions;  non-embryonic pluripotent stem cells, their isolation, expansion, and usage, respectively.  The new patents expand on Athersys’ existing portfolio of 14 patents with an additional120 global patent applications supporting its stem cell technology and MultiStem product platform.  Based in Cleveland, Ohio, Athersys, Inc is a biopharmaceutical company producing non-embryonic cell product candidates for the treatment of multiple diseases. Athersys also develops orally administered pharmaceuticals to treat central nervous system disorders, such as narcolepsy, excessive daytime sleepiness, and chronic fatigue associated with Parkinson’s disease and schizophrenia.  In late December the biotech company entered into an alliance with big Pharma, Pfizer, to develop Athersys’ stem cell technology, the announcement sent the stock soaring more than 400%.  The global stem cell market is currently valued at $4.5 billion and growing rapidly at a compound annual rate of 27.3%; the market is expected to be worth $15 billion by 2015.  Another driver for activity in the biopharmaceutical sector has been a recent upsurge in strategic mergers & acquisitions: a 2009 Ernst & Young report revealed merger & acquisition activity was worth $28.5 billion in deals in 2008 in the US alone. The report also explained that the biotech industry has been helped by President Barack Obama’s pronouncement that the US government should spend more than 3% of its GDP on scientific research and development. ATHX has broken through resistance and is trading above its 90 day moving average of $1.98.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Lundin Mining Corporation (TSX: LUN), $4.16, +0.11, 2.72%, is trading in the range of 4.09 and 4.21 today, making gains of 2.72% with pretty heavy volume on the TSX.  This past January LUN hit its 52 week-high of 5.18.  Lundin Mining will release its report for the Full Year and the Fourth Quarter 2009 on February 25, 2010.  The company will also hold a conference call on the same day.  Lundin Mining is a diversified base metals mining company with operations in Portugal, Spain, Sweden and the DRC.

Aastrom Biosciences Inc. (NASDAQ: ASTM), $0.182, -0.029, -13.60%, did not manage to sustain itself above its 52 week-low of 0.20, which it hit in early February.   Aastrom has been trading in the 0.165 to 0.19 range.  Astrom announced that it has approved a one-for-eight reverse stock split of the company’s common stock which will come into effect on February 18, 2010.  After the split Aastrom expects to have around 28.3 million shares of common stock outstanding.  Aastrom is a regenerative medicine company which deals with clinical development of autologous cell products which occurs when cells are collected from a patient and returned to that same patient for the repair or regeneration of multiple human tissues.

China Tel Group Inc. (OTCBB: CHTL), $1.54, +0.345, 28.87%, has been trading in a range of 1.411 to 1.80 today which is not far off from its 52 week-high of 2.00 from the beginning of January.  The company is responsible for offering fixed telephony, conventional long distance, high-speed wireless broadband and telecommunications infrastructure engineering and construction services, focusing on networks in Asia and South America.  China Tel announced that it has received the first combined instalments of two stock purchase agreements which is a total investment of $640 million into the company. The combined investment represents 48% of the total outstanding shares, putting ChinaTel at a value in excess of $1.33 billion.

Northgate Minerals Corporation (AMEX: NXG), $2.632, +0.172, 6.98%, is a Canadian based gold and copper producer with projects in Canada and Australia.  Shares of NXG are reaching levels between 2.50 to 2.67 today.  Northgate is proceeding with the development of the Young-Davidson mine in Ontario.  Some of the mine highlights include 2.8 million ounces of proven and probable reserves, annual production of 180,000 ounces of gold, employment for 600 people during the two year construction period and direct employment for 275 people over the 15 year life of the mine.

Soho Resources Corp. (TSXV: SOH), $0.09, +0.015, 20.00%, is heavily traded on the TSX Venture today with gains of over 20%, trading at the day’s high of 0.09 touching down on a low of 0.07.  Soho Resources Corp. is a junior exploration and development company strategically focused on gold, silver and base metals in the prolific Sierra Madre Belt of Mexico.  The significant traffic in volume and share price increase is not attributable to any news release.

About Picksthatmove.com

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com’s affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  Please follow us on Twitter and Facebook for further investment updates.  We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.

ConjuChem Biotechnologies Inc. (TSE:CJB) gained 15.00% up to $0.115 on no news since the end of January when the company announced its fiscal 2009 year end results. Based in Montreal, Quebec, ConjuChem Biotechnologies is biotechnology firm dedicated to the discovery of therapeutics focused on curing diabetes, cancer and HIV. The biotech firm currently has three drug candidates in development and the company’s diabetes treatment PC-DAC Exendin-4 recently achieved promising glycemic control and weight loss in Phase II clinical trials for Type 2 diabetes.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rose 6.37% up to $1.67 on news the company reported financial results for the quarter and 12 month period ended December 31, 2009.  The biotech company posted profits of $3 million, or +3 cents per share, up from a loss of $69.6 million, or - 72 cents per share in 2008, a loss due chiefly to cost absorbed as part of $72 million purchase of the biotechnology company Pharmacopeia.  Revenue grew 13% to $14 million compared to $12.4 million for the same period in 2008.  Ligand also provided guidance for 2010 and updates on key programs. Based in San Diego, California, Ligand discovers and develops new drugs for unmet medical needs including hepatitis, muscle wasting, frailty, inflammation, anaemia, asthma, rheumatoid arthritis and osteoporosis. Ligand has strategic partnerships with big pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck, Pfizer, Roche, Celgene, and Cephalon etc.

Naturewell, Inc. (OTC:NAWL) jumped 50.00% up to $0.0003 on no news. Based in San Diego, California, Naturewell researches and develops proprietary healthcare products for various conditions, including its migraine medication, Migraspray. NAWL has gained 200% since October 2009.

Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) advanced 23.81% up to $3.90 on no news. Based in Seattle, Washington, Trubion is a biopharmaceutical company creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer.

 To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Compugen Ltd.  (NASDAQ:CGEN) rose 7.07% up to $ 4.39 on news the company posted narrower losses than expected in their 2009 Q4 results. During the last quarter of 2009 the company benefitted from a partnership with Pfizer to develop their pipeline, and successfully raised capital to further fund discoveries in 2010.  The company made progress and received promising results from studies of in vivo trails for various treatment candidates for cancer and inflammation.  Based in Tel Aviv, Israel, Compugen is a drug company which discovers and commercializes its candidates by early-stage licensing and co-development deals. The company’s business is focused on developing and using predictive computer-based discovery platforms to determine therapeutic drug candidates and diagnostic biomarker candidates. GCEN stock has gained 698% since last February.

Oncolytics Biotech, Inc. (TSE:ONC) jumped 14.95% up to $3.23 on no news; however the company is expected to begin enrolment for its upcoming Phase 3 trial for Reolysin.  Reolysin is being developed as a therapeutic for the treatment of head and neck cancers.  Headquartered in Calgary, Alberta, Oncolytics Biotech, Inc is a biopharmaceutical company which discovers and develops therapeutic products for the treatment of cancer.  The company currently has more than a dozen trials at various stages in the US, UK and Canada for their lead drug candidate Reolysin. The company has a market cap of about $183 million and the financial wherewithal to fund the company through Phase 3 FDA evaluations.  According to Research and Markets the global head and neck cancer market is expected to grow at a rate of 8.3% annually for the next six years to reach $1,809M by 2016.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

Western Coal Corp. (TSX: WTN), $3.43, +0.28, 8.89%, is making considerable gains today trading near the day’s high of 3.47 touching down on a low of 3.26.  Western Coal released its operating results for the three and nine month period ending December 31, 2009.  Some key points included consolidated revenues of $118.7 million were 10% higher than fiscal second quarter 2010, attributable to 175,000 tonnes of coal sold at previous coal year prices.  Western Coal also reports that they commenced operations on a permit for Maple Coal surface mine which increases reserves of marketable tons to over 10 million short tons, which is a 67% increase in the Maple surface reserves.  Western is a producer of high quality metallurgical and thermal coal from mines located in northeast British Columbia and West Virginia.

Arco Resources Corp. (TSXV: ARR), $0.06, +0.015, 33.33%, is trading in a tight spread between 0.045 and 0.07, coming close to reaching its 52 week-high of 0.075.  The company holds a 100% interest in six mineral claim blocks in Oaxaca, Mexico.  Arco reported on its underground sampling program from its 386 hectare Taviche property.  The results showed a 230 metre long shoot of the vein with silver-gold values averaging 173 g/t silver (Ag) and 1.5 g/t gold (Au).  Other samplings identified a similar 220 metre long shoot averaging 161 g/t Ag and 2.18 g/t Au.  The Tavish vein is a silver-gold-bearing quartz vein.

Rexahn Pharmaceuticals Inc. (AMEX: RNN), $0.76, +0.07, 10.14%, is a clinical stage pharmaceutical company focused on treatments of cancer, CNS disorders, sexual dysfunction and other medical needs.  The company has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin™ and Zoraxel™.  RNN has been trading today between the 0.68 and 0.825 range on gains of over 10%.  Rexahn is presenting today at the 12th Annual BIO CEO & Investor Conference.  Rexhan’s Chairman and CEO, Dr. Chang H. Ahn, will speak about a business overview and provide updates on Rexahn’s recent clinical and financing milestones.

Cord Blood America Inc. (OTCBB: CBAI), $0.01, +0.001, 11.11%, is trading the day away in the range of 0.009 and 0.011, with the 52 week-high sitting at 0.02.  Cord Blood announced yesterday that it has finalized an agreement to process and store cord blood specimens for BioCells, Inc.  BioCells is the second largest stem cell storage company in Argentina with annual revenues of 1.5M (USD) and 12 locations throughout that country.  Cord Blood America facilitates umbilical cord blood stem cell preservation for expectant parents and their children.

Cell Therapeutics Inc. (NASDAQ: CTIC), $0.78, +0.14, 21.88%, focuses on the development, acquisition and commercialization of drugs for the treatment of cancer.  On February 11, 2010, the Cell Therapeutic’s team will host a conference call to review the Company’s 2009 fourth quarter and year-end achievements and financial results.  Cell Therapeutics is trading between 0.74 and 0.80, with its 52 week-high sitting at 2.23.

About Picksthatmove.com

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies. PicksThatMove.com is not a registered investment advisor or broker-dealer. PicksThatMove.com’s affiliates, offices, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  Please follow us on Twitter and Facebook for further investment updates.  We recommend you do your own Due Diligence before investing in any of the stocks mentioned above.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) rose 12.23% up to $2.05 on no news today; however anticipation of tomorrow’s Q4 financial results is driving the stock.  Oculus will host a conference call tomorrow at 4:30 EST for all shareholders and interested parties. Last week the company announced marketing plans for it’s recently FDA approved Microcyn Technology platform for the irrigation and management of post-surgical wounds. The company has received clearance from health agencies throughout the US, Europe, India, China and Mexico and select Middle East countries. Oculus’ Microcyn Technology has treated over two million patients worldwide and has been used in 30 clinical studies, without any adverse effect.  Based in Petaluma, California, Oculus Innovative Sciences is a biopharmaceutical company which develops, manufactures and markets products based upon Microcyn Technology platform, including formulations designed to significantly reduce the need for antibiotics to fight infections.

Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) jumped 18.70% up to $2.73 on no news. Next week Somaxon’s CEO Richard Pascoe, will participate at the 12th Annual BIO CEO & Investor Conference at the Waldorf-Astoria in New York, Monday, February 8th at 9:30 A.M. In January the sleep drug maker refilled its New Drug Application (NDA) on behalf of Silenor (doxepin) with the FDA, seeking approval for its drug candidate for the treatment of insomnia.  On December 7th 2009, the FDA declined Silenor for the second time that year; the stock spiralled down some 72% by mid-December, where it was trading around $0.928.  Fortunately the clinical safety of the drug was not an issue for the FDA; however the government agency was not satisfied with the efficacy standard for sustained sleep required to maintain effectiveness in adults with insomnia. The review is expected to be completed sometime in mid-March 2010. Headquartered in San Diego, California, Somaxon is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the central nervous system such as insomnia.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter

BSD Medical Corporation (NASDAQ:BSDM) jumped 45.51% up to $2.43 on news the Journal of the National Cancer Institute published an article on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” The article stated that, “Successful use of targeted heat therapy with chemotherapy in treatment of soft-tissue sarcoma has given US advocates of local hyperthermia new hope that the treatment they so believe in will now be taken seriously.” Last fall a Phase III study, which applied the BSD-2000 Hyperthermia System, showed that patients with high risk soft-tissue sarcomas were 30% more likely to be alive and cancer free almost three years after beginning the treatment if heat therapy was added to chemotherapy. Headquartered in Salt Lake City, Utah, BSD Medical Corporation develops, manufactures, commercializes, and services systems used for therapeutic treatments of cancer and other diseases.   The company is specialized in researching and developing therapeutics which bio-enhance current treatments.

Repros Therapeutics Inc. (NASDAQ:RPRX) gained 25.97% up to $0.94 on news the company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the company may begin its Investigational New Drug Application for the study of oral Androxal in the treatment of hypogonadal men with Type II Diabetes with a Phase IIa trial. Based in The Woodlands, Texas, Repros Therapeutics is a development-stage biopharmaceutical company developing drug therapies for the treatment of serious female pelvic conditions, such as treatment of uterine fibroids, anaemia associated with excessive menstrual bleeding relating to uterine fibroids, and anaemia associated with uterine fibroids and endometriosis.  Repros Therapeutics has three late stage drug candidates in trials including Androxal, a hormone treatment of for low testosterone levels in men.  RPRX is surging on heavy volume with 9,067,032 shares trading actively.

To be kept up to date on all of our hot stock information join us at Picks That Move.

About PicksThatMove.com:

PicksThatMove.com is an independent electronic publication that provides information on selected publicly traded companies.  PicksThatMove.com is not a registered investment advisor or broker-dealer.  PicksThatMove.com affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock. 

Subscribe NOW to our newsletters by clicking on the following link: http://picksthatmove.com/join-now/.   Feel free to visit our communities on Facebook and Twitter